<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799963</url>
  </required_header>
  <id_info>
    <org_study_id>22-EU-03</org_study_id>
    <nct_id>NCT05799963</nct_id>
  </id_info>
  <brief_title>ALPHA LONG Study- BioMatrix AlphaTM Stent Study in Patients With CAD</brief_title>
  <official_title>A Prospective Multicenter Single Arm Trial to Assess the Safety and Effectiveness of Additional Sizes of the BioMatrix AlphaTM (Cobalt Chromium Biolimus A9TM Drug-eluting Stent) - ALPHA LONG Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosensors Europe SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosensors Europe SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, open-label single-arm study designed to enroll 85 patients in up&#xD;
      to 15 centers in up to 3 European countries.&#xD;
&#xD;
      All patients will be followed up for 9 months. The &quot;BMX Alpha Registry&quot; study will serve as&#xD;
      reference and historic comparator.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate if PCI performed using the additional sizes of the&#xD;
      BioMatrix AlphaTM stent results in similar safety and efficacy outcomes as the currently&#xD;
      approved (CE marked) sizes of BioMatrix Alpha.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 14, 2023</start_date>
  <completion_date type="Anticipated">March 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, multi-center, open-label single-arm study. Prospective, multi-center, open-label single-arm study designed to enroll 85 patients in up to 15 centers in up to 3 European countries.&#xD;
All patients will be followed up for 9 months. The &quot;BMX Alpha Registry&quot; study will serve as reference and historic comparator.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Target Lesion Failure (TLF)</measure>
    <time_frame>at 9 months after index procedure</time_frame>
    <description>Primary endpoint is the rate of Target Lesion Failure (TLF) at 9 months defined as cardiovascular death or target vessel myocardial infarction or clinically indicated target lesion revascularization (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Cardiovascular Death (CD)</measure>
    <time_frame>at 9 months after index procedure</time_frame>
    <description>Incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Target Vessel Myocardial Infarction</measure>
    <time_frame>at 9 months after index procedure</time_frame>
    <description>Target Vessel Myocardial Infarction (TV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Clinically indicated Target Lesion Revascularization</measure>
    <time_frame>at 9 months after index procedure</time_frame>
    <description>Clinically indicated Target Lesion Revascularization (ci-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Target Vessel Revascularization</measure>
    <time_frame>at 9 months after index procedure</time_frame>
    <description>Target Vessel Revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Stent thrombosis (definite and/or probable)</measure>
    <time_frame>at 9 months after index procedure</time_frame>
    <description>incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of of participants with All-cause mortality</measure>
    <time_frame>at 9 months after index procedure</time_frame>
    <description>incidence</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>BioMatrix Alpha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive the BioMatrix Alpha as per treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioMatrix Alpha</intervention_name>
    <description>Patient will be treated with BioMatrix Alpha</description>
    <arm_group_label>BioMatrix Alpha</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must provide written informed consent&#xD;
&#xD;
          2. Patient is at least 18 years old&#xD;
&#xD;
          3. Patients scheduled to undergo PCI of a de novo lesion(s) with reference vessel&#xD;
             diameter and lesion length suitable for treatment with at least one study device&#xD;
&#xD;
          4. Patients who agree to comply with the follow up requirements&#xD;
&#xD;
          5. Patients with a life expectancy of &gt; 1 year at time of consent&#xD;
&#xD;
          6. Patients eligible to receive for ≥6 months either dual anti-platelet therapy (DAPT,&#xD;
             i.e. 75 mg clopidogrel or another P2Y12 inhibitor per choice of the investigator, and&#xD;
             75-100 mg aspirin) or a combination of an oral anti-coagulant (Vitamin K antagonist or&#xD;
             novel anti-coagulant) and a single anti-platelet agent&#xD;
&#xD;
          7. Hemodynamically stable patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide informed consent&#xD;
&#xD;
          2. Currently participating in another clinical trial&#xD;
&#xD;
          3. Planned surgery ≤6 months of PCI unless DAPT or combination&#xD;
             anti-thrombotic/anti-platelet therapy is maintained throughout the peri-surgical&#xD;
             period&#xD;
&#xD;
          4. Planned use of additional stents other than BioMatrix AlphaTM during the index&#xD;
             procedure.&#xD;
&#xD;
          5. Patients with a life expectancy of &lt; 1 year&#xD;
&#xD;
          6. Known hypersensitivity or contraindication to aspirin, clopidogrel (or to any other&#xD;
             P2Y12 inhibitor if applicable), cobalt chromium, zinc, Biolimus A9 or a sensitivity to&#xD;
             contrast media, which cannot be adequately pre-medicated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scot Garg, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Blackburn Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Schuette</last_name>
    <phone>+41(0)218048000</phone>
    <email>d.schuette@biosensors.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keith Oldroyd, MD</last_name>
    <phone>+41(0)218048000</phone>
    <email>k.oldroyd@biosensors.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Birmingham (UHB)</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Sohail Khan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Blackburn Hospital</name>
      <address>
        <city>Blackburn</city>
        <zip>BB2 3HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Scot Garg, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hull University Teaching Hospitals (HUTH)</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Raj Chelliah</last_name>
    </contact>
    <contact_backup>
      <phone>01482 875875</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>United Lincolnshire Hospitals (ULH)</name>
      <address>
        <city>Lincoln</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Kelvin Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Grange University Hospital, Newport</name>
      <address>
        <city>Newport</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Albert Edward Infirmary</name>
      <address>
        <city>Wigan</city>
        <zip>WN1 2NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Abhishek Kumar</last_name>
    </contact>
    <contact_backup>
      <email>abhishek.kumar@wwl.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 23, 2023</study_first_submitted>
  <study_first_submitted_qc>March 23, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>April 27, 2023</last_update_submitted>
  <last_update_submitted_qc>April 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

